Related references
Note: Only part of the references are listed.Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa
Michelle Lee et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2021)
Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an In Vitro Pharmacodynamic Model
Maria Montero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia
Shampa Das et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)
The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms
Mandee Noval et al.
CURRENT INFECTIOUS DISEASE REPORTS (2020)
Resistance to ceftazidime-avibactam and underlying mechanisms
Yuhang Wang et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)
Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of Pseudomonas aeruginosa
Emel Mataraci Kara et al.
INFECTIOUS DISEASES (2020)
Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model
Joan Gomez-Junyent et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactam
Frieder Schaumburg et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones
Maria M. Montero et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2019)
Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa
Sandra Mikhail et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Activity of colistin alone or in combination with rifampicin or meropenem in a carbapenem-resistant bioluminescent Pseudomonas aeruginosa intraperitoneal murine infection model
Yun Cai et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa
Pablo A. Fraile-Ribot et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection Model
M. Montero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates
Paolo Gaibani et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2017)
Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria
Mark D. Gonzalez et al.
ANNALS OF LABORATORY MEDICINE (2017)
Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments
Thomas Tangden et al.
INFECTIOUS DISEASES (2017)
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates
Romney M. Humphries et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain
Ester del Barrio-Tofino et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the D179Y Substitution in the KPC-2 β-Lactamase
Fabrice Compain et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases
Ghady Haidar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms
S. K. B. Sy et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Steven Marshall et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Distinctive Binding of Avibactam to Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria
Abdelhamid Asli et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate
Juan P. Horcajada et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
In Vitro Pharmacodynamics of Various Antibiotics in Combination against Extensively Drug-Resistant Klebsiella pneumoniae
Tze-Peng Lim et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
Romney M. Humphries et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
The increasing threat of Pseudomonas aeruginosa high-risk clones
Antonio Oliver et al.
DRUG RESISTANCE UPDATES (2015)
Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa
Marisa L. Winkler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen
Etienne de Montmollin et al.
INTENSIVE CARE MEDICINE (2014)
Systematic Review and Meta-Analysis of In Vitro Synergy of Polymyxins and Carbapenems
Oren Zusman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study
Luisa Sorli et al.
BMC INFECTIOUS DISEASES (2013)
Characterization of -lactamase and porin mutants of Enterobacteriaceae selected with ceftarolineavibactam (NXL104)
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients
S. M. Garonzik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Creeping baselines and adaptive resistance to antibiotics
Lucia Fernandez et al.
DRUG RESISTANCE UPDATES (2011)
A Novel Approach to Pharmacodynamic Assessment of Antimicrobial Agents: New Insights to Dosing Regimen Design
Vincent H. Tam et al.
PLOS COMPUTATIONAL BIOLOGY (2011)
The Combination of Meropenem and Levofloxacin Is Synergistic with Respect to both Pseudomonas aeruginosa Kill Rate and Resistance Suppression
Arnold Louie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria
D. Plachouras et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Effectiveness and Safety of Colistin for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections
M. Montero et al.
INFECTION (2009)
Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model
BW Gunderson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Share Paper
